Literature DB >> 30473172

Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry.

Marcello Deraco1, Eran Nizri2, Olivier Glehen3, Dario Baratti4, Jean-Jacques Tuech5, Jean-Marc Bereder6, Vahan Kepenekian3, Shigeki Kusamura4, Diane Goere7.   

Abstract

BACKGROUND: Well differentiated papillary peritoneal mesothelioma (WDPPM) is a rare variant of mesothelioma which affects mainly women in the reproductive age. The disease may present multifocally and recur after primary resection. Our aim was to describe the outcomes of cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in this disease.
METHODS: Patients with histological diagnosis of WDPPM were retrieved from the PSOGI registry. Demographical and clinical data were extracted as well as outcomes data (overall survival (OS) and recurrence free survival (RFS)).
RESULTS: We analyzed 45 patients for whom complete data was available. The majority of patients were women (n = 33, 73%) with a median age of 44 years. Preoperative chemotherapy (CT) was administered in 8 patients (18%). Median peritoneal carcinomatosis index was 9 (1-30), and complete cytoreduction was achieved in 69% of patients. There was one case (2%) of postoperative mortality, and 24% rate of severe morbidity. Overall, there were 4 deaths and 5 years OS was 80%. 8 patients (18%) had disease recurrence, all within 5 years from operation. On univariate analysis preoperative CT, high PCI and severe morbidity were associated with reduced RFS. On multivariate analysis, only preoperative CT (HR = 32.6, 95% CI: 2.39-446.2, p = 0.009) and high PCI (HR = 21.7, 95% CI: 1.11-425.7, p = 0.04) remained significant risk factors.
CONCLUSIONS: WDPPM can be a lethal disease with substantial recurrence even after aggressive treatment. Patients presenting with extensive disease or disease recurrence after surgical excision are at increased risk for relapse. CRS + HIPEC can be safely applied to WDPPM in specialized centers.
Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30473172     DOI: 10.1016/j.ejso.2018.10.065

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  3 in total

Review 1.  Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel.

Authors:  Alberto M Marchevsky; Andras Khoor; Ann E Walts; Andrew G Nicholson; Yu Zhi Zhang; Victor Roggli; John Carney; Anja C Roden; Henry D Tazelaar; Brandon T Larsen; Nolwenn LeStang; Lucian R Chirieac; Sonja Klebe; Ming-Sound Tsao; Marc De Perrot; Andrew Pierre; David M Hwang; Yin P Hung; Mari Mino-Kenudson; William Travis; Jennifer Sauter; Mary Beth Beasley; Françoise Galateau-Sallé
Journal:  Mod Pathol       Date:  2019-09-04       Impact factor: 7.842

2.  Peritoneal mesothelioma in Sweden: A population-based study.

Authors:  Peter H Cashin; Gabriella Jansson Palmer; Dan Asplund; Wilhelm Graf; Ingvar Syk
Journal:  Cancer Med       Date:  2019-09-04       Impact factor: 4.452

3.  Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma.

Authors:  Raunak Shrestha; Noushin Nabavi; Stanislav Volik; Shawn Anderson; Anne Haegert; Brian McConeghy; Funda Sar; Sonal Brahmbhatt; Robert Bell; Stephane Le Bihan; Yuzhuo Wang; Colin Collins; Andrew Churg
Journal:  Cancers (Basel)       Date:  2020-06-13       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.